Antibody–drug conjugates have emerged as ... stages that employ payloads with distinct mechanisms of action, from immune agonist payloads to protein degrader payloads and novel cytotoxic payloads.

A recent study has introduced a novel class of antibody-drug conjugates (ADCs) targeting trophoblast cell surface antigen 2 (TROP2), a protein overexpressed in pancreatic ductal adenocarcinoma (PDAC), ...

IPH4502 is a novel and differentiated topoisomerase I inhibitor ADC designed to precisely target Nectin-4, a cell adhesion ...

Co., Ltd. The partnership will leverage MediLink's TMALIN antibody-drug conjugate (ADC) platform to develop a novel LRRC15 ADC, known as ZL-6201, which includes an antibody discovered by Zai Lab.

This results in T reg cell depletion and a restored antitumor immune response ... optimized antibody–drug conjugates, to bispecific antibodies and chimeric antigen receptors for cell-based ...

Elevation Oncology Inc. has nominated EO-1022 as its HER3 antibody-drug conjugate (ADC) development candidate for the treatment of solid tumors that express HER3. EO-1022 is currently advancing ...

An antibody-drug conjugate (ADC) targeting CD30 ... TNFRSF molecules and ligands are targeted on cells of the immune system to boost immune activity against a tumor cell or on tumor cells to ...

IMP761 is the world’s first LAG-3 agonist antibody, demonstrating significant potential to treat a range of autoimmune diseases by restoring immune balance. Encouraging preclinical data showing ...